Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma

NCT06388889 is registered in ClinicalTrials.gov with Areteia Therapeutics as lead sponsor.

NCT NCT06388889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants With Severe Eosinophilic Asthma
Lead sponsor
Areteia Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
June 12, 2024
Completion date
December 8, 2025
Enrollment
509 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic asthma